Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CymaBay Therapeutics
Biotech
CymaBay board pushed for 50 cent top up to Gilead's $32.50 offer
Gilead placed its “best and final” offer to buy CymaBay on January 30: $32.50 per share in cash. But the biotech’s board wanted exactly 50 cents more.
Annalee Armstrong
Feb 26, 2024 10:49am
Gilead pays $4.3B for CymaBay's late-stage liver disease med
Feb 12, 2024 9:01am
Ipsen posts mixed liver disease data on Intercept, CymaBay rival
Nov 14, 2023 5:55am
CymaBay's liver drug improves biomarkers, itching in phase 3
Sep 7, 2023 10:15am
Roivant founder departs for White House bid—Chutes & Ladders
Feb 24, 2023 9:30am
Rubius execs depart as the walls close in—Chutes & Ladders
Nov 4, 2022 9:30am